JP2019518052A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518052A5
JP2019518052A5 JP2018565750A JP2018565750A JP2019518052A5 JP 2019518052 A5 JP2019518052 A5 JP 2019518052A5 JP 2018565750 A JP2018565750 A JP 2018565750A JP 2018565750 A JP2018565750 A JP 2018565750A JP 2019518052 A5 JP2019518052 A5 JP 2019518052A5
Authority
JP
Japan
Prior art keywords
diabetes
tumor
treatment
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565750A
Other languages
English (en)
Japanese (ja)
Other versions
JP6900406B2 (ja
JP2019518052A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/088030 external-priority patent/WO2017215588A1/zh
Publication of JP2019518052A publication Critical patent/JP2019518052A/ja
Publication of JP2019518052A5 publication Critical patent/JP2019518052A5/ja
Application granted granted Critical
Publication of JP6900406B2 publication Critical patent/JP6900406B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565750A 2016-06-16 2017-06-13 Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物 Active JP6900406B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610428049 2016-06-16
CN201610428049.6 2016-06-16
CN201610674021 2016-08-15
CN201610674021.0 2016-08-15
PCT/CN2017/088030 WO2017215588A1 (zh) 2016-06-16 2017-06-13 作为Akt抑制剂的二氢吡唑氮杂卓类化合物

Publications (3)

Publication Number Publication Date
JP2019518052A JP2019518052A (ja) 2019-06-27
JP2019518052A5 true JP2019518052A5 (enExample) 2020-05-14
JP6900406B2 JP6900406B2 (ja) 2021-07-07

Family

ID=60663995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018565750A Active JP6900406B2 (ja) 2016-06-16 2017-06-13 Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物

Country Status (6)

Country Link
US (1) US10654868B2 (enExample)
EP (1) EP3473628B1 (enExample)
JP (1) JP6900406B2 (enExample)
KR (1) KR102351270B1 (enExample)
CN (1) CN109311908B (enExample)
WO (1) WO2017215588A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3725791T (pt) * 2017-12-13 2023-04-04 Harbin Zhenbao Pharmaceutical Co Ltd Sal que serve como inibidor de akt e seu cristal
WO2022121788A1 (zh) * 2020-12-07 2022-06-16 南京正大天晴制药有限公司 一种吡唑并氮杂卓类akt抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
CN101094833A (zh) * 2004-07-12 2007-12-26 伊邓药品公司 四肽类似物
US8207180B2 (en) * 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2002836B1 (en) * 2007-05-31 2010-10-20 Nerviano Medical Sciences S.r.l. Cyclocondensed azaindoles active as kinase inhibitors
EP2240029A4 (en) * 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
JP2011525928A (ja) 2008-06-26 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Akt活性の阻害剤
CN103298461A (zh) 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法

Similar Documents

Publication Publication Date Title
JP2016518337A5 (enExample)
JP2015147774A5 (enExample)
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
EP3835296A4 (en) KETOAMIDE COMPOUND AND METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
JP2016065085A5 (enExample)
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
JP2018202656A5 (enExample)
JP2020536085A5 (enExample)
JP2014530840A5 (enExample)
JP2009536652A5 (enExample)
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP3318282A4 (en) AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF
SG11202105540YA (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
JP2016540030A5 (enExample)
JP2017537912A5 (enExample)
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
JP2017531686A5 (enExample)
JP2017197541A5 (enExample)
HUE053472T2 (hu) Gyengén oldódó komplex vagy szolvátja, gyógyászati készítmény és alkalmazása
JP2019518052A5 (enExample)
WO2017105881A8 (en) Deuterated compounds for treating pain
EP3490663A4 (en) RESPIRATOR-RELATED PARASTERNAL ELECTROMYOGRAPHIC RECORDING IN NEUROSTIMULATORS
SMT202200150T1 (it) Derivati penamici o loro sali, composizioni farmaceutiche e loro usi
HK1243709A1 (zh) 可用於治疗阿尔茨海默氏病的四氢呋喃稠合的氨基氢噻嗪衍生物